Belgium’s Agomab Therapeutics debuted on the Nasdaq with a $716 million valuation, despite shares slipping 8% amid a selective market. While biotech activity is rebounding, investor caution remains high for clinical-stage firms. IPOX® Research Associate Lukas Muehlbauer noted that while the window for drugmakers remains open, it is effectively closed for software firms, highlighting a significant divergence in risk appetite across sectors in the current IPO landscape.

Reuters highlights Forgent Power’s successful $8 billion NYSE debut, underscoring the enduring demand for AI infrastructure. IPOX® Research Associate Lukas Muehlbauer provided expert commentary, noting that the midpoint pricing signals "healthy but disciplined investor demand" amid volatility. He emphasized Forgent’s strategic value as a critical infrastructure provider, offering unique exposure to the AI sector distinct from traditional tech firms, driven by surging data center needs.

Reuters features IPOX® Associate Lukas Muehlbauer’s commentary on York Space Systems’ $4.75 billion NYSE debut. Muehlbauer notes that the successful listing signals a receptive market for defense and space stocks in 2026, setting the stage for the highly anticipated SpaceX IPO. He also analyzes York’s acquisition of ATLAS Space Operations, cautioning that despite the push into software services, the stock will likely remain volatile and sensitive to government spending news in the near term.

Reuters features IPOX® Research Associate Lukas Muehlbauer’s analysis on Eikon Therapeutics' upcoming $908 million IPO. Muehlbauer highlights the premium placed on CEO Roger Perlmutter’s leadership and the company’s Nobel Prize-backed drug discovery platform. He further contrasts Eikon with recent listings like Aktis Oncology, explaining how Eikon aims to overcome historical toxicity challenges in immune-stimulating drugs. This listing signals renewed momentum for the biotech sector following a challenging 2025.

Bloomberg features IPOX® CEO Josef Schuster’s analysis on the "Once Upon a Farm" IPO, co-founded by Jennifer Garner. Discussing the "Hollywood IPO Curse," Schuster warns that celebrity-backed deals historically underperform, citing an "eight out of 11" failure rate. He urges investors to prioritize operational expertise and management resumes over star power. The article underscores the critical importance of evaluating business fundamentals versus celebrity marketing when assessing new public listings.